Annual General Meeting on 19 March 2015
The Annual General Meeting of Novo Nordisk A/S will be held on:
Thursday 19 March 2015 at 2.00 pm (CET)
at Bella Center, entrance West, Center Boulevard 5, 2300 Copenhagen S, Denmark.
The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors and Appendix 2: Revised Remuneration Principles is enclosed.
Board of Directors - proposed changes in composition
All board members elected by the Annual General Meeting are up for election. Helge Lund and Hannu Ryöppönen do not seek re-election.
The Board of Directors proposes re-election of the following board members elected by the shareholders: Göran Ando (chairman), Jeppe Christiansen (vice chairman), Bruno Angelici, Liz Hewitt, and Thomas Paul Koestler.
The Board of Directors proposes that Sylvie Grégoire, Eivind Kolding and Mary Szela are elected as new members to the Board of Directors at the Annual General Meeting.
Ms Grégoire is former president of Human Genetic Therapies Shire PLC, US and Switzerland, from 2007 to 2013. The Board of Directors recommends election of Ms Grégoire primarily because of her deep knowledge of the regulatory environment in both the US and the EU having experience with all phases of the product life cycle from discovery, registration, pre-launch and managing the life cycle while on the market. In addition, Sylvie Grégoire has financial insight from i.a. P&L responsibility.
Mr Kolding is chief executive officer of Novo A/S, Denmark. The Board of Directors recommends election of Mr Kolding primarily because of his extensive executive experience in large multinational companies headquartered in Denmark within regulated markets and his significant financial knowledge.
Ms Szela is chief executive officer of Melinta Therapeutics, Inc., US. The Board of Directors recommends election of Ms Szela primarily because of her deep understanding of the clinical, regulatory and marketing aspects of the pharmaceutical industry in North America having both operational and strategic experience.
Further information
| Media: | ||
| Kristine Kruse Zeij | +45 3075 1987 | kstk@novonordisk.com (mailto:kstk@novonordisk.com) |
| Ken Inchausti (US) | +1 609 514 8316 | kiau@novonordisk.com (mailto:kiau@novonordisk.com) |
| Investors: | ||
| Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com (mailto:krop@novonordisk.com) |
| Jannick Lindegaard Denholt | +45 3079 8519 | jlis@novonordisk.com (mailto:jlis@novonordisk.com) |
| Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com (mailto:dabo@novonordisk.com) |
| Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com (mailto:mrz@novonordisk.com) |
| Frank Daniel Mersebach (US) | +1 609 235 8567 | fdni@novonordisk.com (mailto:fdni@novonordisk.com) |
Company announcement No 13 / 2015
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
